Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

Also called NCT02922036

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
EBR Systems, Inc. (from the registry)
Registry
  • NCT NCT02922036
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, France, Germany, Italy, Netherlands, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT02922036. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-17 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
Acronym
SOLVE-CRT
Condition
Heart Failure
Intervention (Device)
WiSE System
Lead sponsor
EBR Systems, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02922036
Content hash
7af569f434fb876a26ce4153c6e8b4c704517e219aedf19e3101c50947bf28dc